A novel protein glycan biomarker and LCAT activity in metabolic syndrome

European Journal of Clinical Investigation

Volumn 45, Issue 8, 2015, Pages 850-859

  Gruppen, Eke G ^a   Connelly, Margery A ^b   Otvos, James D ^b   Bakker, Stephan J L ^a   Dullaart, Robin P F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b LABORATORY CORPORATION OF AMERICA   (United States)

Author keywords

Diabetes mellitus; Glycoproteins; High sensitivity C reactive; Lecithin:cholesterol acyltransferase; Metabolic syndrome

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; GLYCAN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; SERUM AMYLOID A; TUMOR NECROSIS FACTOR ALPHA; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEOGLYCAN; TRIACYLGLYCEROL;

ACUTE PHASE RESPONSE; ADULT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; AGED; BLOOD; CASE CONTROL STUDY; COMPLICATION; METABOLISM; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; STATISTICAL MODEL;

ADULT; AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BIOMARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LINEAR MODELS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; PROTEOGLYCANS; SERUM AMYLOID A PROTEIN; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84937412140     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12481     Document Type: Article

References (55)

1. Rousset X, Shamburek R, Vaisman B, Amar M, Remaley AT. Lecithin cholesterol acyltransferase: an anti-or pro-atherogenic factor? Curr Atheroscler Rep 2011;13:249-56.
2. Kunnen S, Van Eck M. Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis? J Lipid Res 2012;53:1783-99.
3. de Vries R, Borggreve SE, Dullaart RP. Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus. Clin Lab 2003;49:601-13.
4. Glomset JA. The plasma lecithin:cholesterol acyltransferase reaction. J Lipid Res 1968;9:155-67.
5. Calabresi L, Simonelli S, Gomaraschi M, Franceschini G. Genetic lecithin: cholesterol acyltransferase deficiency and cardiovascular disease. Atherosclerosis 2012;222:299-306.
6. Hovingh GK, Hutten BA, Holleboom AG, Petersen W, Rol P, Stalenhoef A et al. Compromised LCAT function is associated with increased atherosclerosis. Circulation 2005;112:879-84.
7. Dullaart RP, Perton F, Sluiter WJ, de Vries R, van Tol A. Plasma lecithin: cholesterol acyltransferase activity is elevated in metabolic syndrome and is an independent marker of increased carotid artery intima media thickness. J Clin Endocrinol Metab 2008;93:4860-6.
8. Calabresi L, Baldassarre D, Simonelli S, Gomaraschi M, Amato M, Castelnuovo S et al. Plasma lecithin:cholesterol acyltransferase and carotid intima-media thickness in European individuals at high cardiovascular risk. J Lipid Res 2011;52:1569-74.
9. Dullaart RP, Perton F, van der Klauw MM, Melanie M, Hillege HL, Sluiter WJ et al. High plasma lecithin: cholesterol acyltransferase activity does not predict low incidence of cardiovascular events: possible attenuation of cardioprotection associated with high HDL cholesterol. Atherosclerosis 2010;208:537-42.
10. Holleboom AG, Kuivenhoven JA, Vergeer M, Hovingh GK, van Miert JN, Wareham NJ et al. Plasma levels of lecithin:cholesterol acyltransferase and risk of future coronary artery disease in apparently healthy men and women: a prospective case-control analysis nested in the EPIC-Norfolk population study. J Lipid Res 2010;51:416-21.
11. Tanaka S, Yasuda T, Ishida T, Fujioka Y, Tsujino T, Miki T et al. Increased serum cholesterol esterification rates predict coronary heart disease and sudden death in a general population. Arterioscler Thromb Vasc Biol 2013;33:1098-104.
12. Dullaart RP, Tietge UJ, Kwakernaak AJ, Dikkeschei BD, Perton F, Tio RA. Alterations in plasma lecithin: cholesterol acyltransferase and myeloperoxidase in acute myocardial infarction: implications for cardiac outcome. Atherosclerosis 2014;234:185-92.
13. Haase CL, Tybjærg-Hansen A, Ali Qayyum A, Schou J, Nordestgaard BG, Frikke-Schmidt R. LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54, 500 individuals. J Clin Endocrinol Metab 2011;97:E248-56.
14. Vohl M, Neville TA, Kumarathasan R, Braschi S, Sparks DL. A novel lecithin-cholesterol acyltransferase antioxidant activity prevents the formation of oxidized lipids during lipoprotein oxidation. Biochemistry 1999;38:5976-81.
15. McPherson PA, Young IS, McEneny J. A dual role for lecithin: cholesterol acyltransferase (EC 2.3. 1.43) in lipoprotein oxidation. Free Radic Biol Med 2007;43:1484-93.
16. McPherson PA, Young IS, McKibben B, McEneny J. High density lipoprotein subfractions: isolation, composition, and their duplicitous role in oxidation. J Lipid Res 2007;48:86-95.
17. Kappelle PJ, de Boer JF, Perton FG, Annema W, de Vries R, Dullaart RP et al. Increased LCAT activity and hyperglycaemia decrease the antioxidative functionality of HDL. Eur J Clin Invest 2012;42:487-95.
18. Dullaart R, Perton F, Kappelle P, de Vries R, Sluiter W, van Tol A. Plasma lecithin: cholesterol acyltransferase activity modifies the inverse relationship of C-reactive protein with HDL cholesterol in nondiabetic men. Biochim Biophys Acta 2010;1801:84-8.
19. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006;58:342-74.
20. Hansel B, Giral P, Nobecourt E, Chantepie S, Bruckert E, Chapman MJ et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 2004;89:4963-71.
21. Kappelle PJ, Bijzet J, Hazenberg BP, Dullaart RP. Lower serum paraoxonase-1 activity is related to higher serum amyloid a levels in metabolic syndrome. Arch Med Res 2011;42:219-25.
22. Jacobs M, Van Greevenbroek M, Van Der Kallen C, Ferreira I, Blaak E, Feskens E et al. Low-grade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease or severity of peripheral arterial disease: the CODAM study. Eur J Clin Invest 2009;39:437-44.
23. Maury E, Brichard S. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 2010;314:1-16.
24. Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and disease. Cell 2006;126:855-67.
25. Arnold JN, Saldova R, Hamid UMA, Rudd PM. Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics 2008;8:3284-93.
26. Mariño K, Bones J, Kattla JJ, Rudd PM. A systematic approach to protein glycosylation analysis: a path through the maze. Nat Chem Biol 2010;6:713-23.
27. Gornik O, Lauc G. Glycosylation of serum proteins in inflammatory diseases. Dis Markers 2008;25:267-78.
28. Bell JD, Brown JC, Nicholson JK, Sadler PJ. Assignment of resonances for 'acute-phase'glycoproteins in high resolution proton NMR spectra of human blood plasma. FEBS Lett 1987;215:311-5.
29. Otvos JD, Shalaurova I, Wolak-Dinsmore J, Connelly MA, Mackey RH, Stein JH et al. GlycA: a composite nuclear magnetic resonance biomarker of systemic inflammation. Clin Chem 2015;61:714-23.
30. Akinkuolie AO, Buring JE, Ridker PM, Mora S. A novel protein glycan biomarker and future cardiovascular disease events. J Am Heart Assoc 2014;3:e001221.
31. Muhlestein JB, May H, Winegar D, Rollo J, Connelly M, Otvos J et al. GlycA and GlycB, Novel NMR Biomarkers of Inflammation Strongly Predict Future Cardiovascular Events, but Not the Presence of Coronary Artery Disease, Among Patients Undergoing Coronary Angiography: the Intermountain Heart Collaborative Study. J Am Coll Cardiol 2014;63:abstract.
32. Simera I, Moher D, Hoey J, Schulz K, Altman D. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
33. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
34. Rutten G, De Grauw W, Nijpels G, Goudswaard A, Uitewaal P, Van der Does F et al. NHG-Standaard Diabetes mellitus type 2. Huisarts Wet 2006;49:137-52.
35. Windgassen EB, Funtowicz L, Lunsford TN, Harris LA, Mulvagh SL. C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians. Postgrad Med 2011;123:114-9.
36. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006;26:847-70.
37. Hazenberg BP, Limburg PC, Bijzet J, van Rijswijk MH. A quantitative method for detecting deposits of amyloid A protein in aspirated fat tissue of patients with arthritis. Ann Rheum Dis 1999;58:96-102.
38. Dullaart R, Sluiter W, Dikkeschei L, Hoogenberg K, Tol A. Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur J Clin Invest 1994;24:188-94.
39. Florén C, Chen C, Franzén J, Albers JJ. Lecithin: cholesterol acyltransferase in liver disease. Scand J Clin Lab Invest 1987;47:613-7.
40. Selvin S. Statistical analysis of epidemiologic data. Oxford: Oxford University Press, 2004.
41. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
42. Wurtz P, Makinen VP, Soininen P, Kangas AJ, Tukiainen T, Kettunen J et al. Metabolic signatures of insulin resistance in 7, 098 young adults. Diabetes 2012;61:1372-80.
43. Wurtz P, Tiainen M, Makinen VP, Kangas AJ, Soininen P, Saltevo J et al. Circulating metabolite predictors of glycemia in middle-aged men and women. Diabetes Care 2012;35:1749-56.
44. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Fogelman AM. HDL as a biomarker, potential therapeutic target, and therapy. Diabetes 2009;58:2711-7.
45. Dullaart RP, de Boer JF, Annema W, Tietge UJ. The inverse relation of HDL anti-oxidative functionality with serum amyloid a is lost in metabolic syndrome subjects. Obesity 2013;21:361-6.
46. Nilsson J, Jovinge S, Niemann A, Reneland R, Lithell H. Relation between plasma tumour necrosis factor-alpha and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1998;18:1199-202.
47. Collins ES, Galligan MC, Saldova R, Adamczyk B, Abrahams JL, Campbell MP et al. Glycosylation status of serum in inflammatory arthritis in response to anti-TNF treatment. Rheumatology (Oxford) 2013;52:1572-82.
48. Loued S, Isabelle M, Berrougui H, Khalil A. The anti-inflammatory effect of paraoxonase 1 against oxidized lipids depends on its association with high density lipoproteins. Life Sci 2012;90:82-8.
49. Ng DS, Maguire GF, Wylie J, Ravandi A, Xuan W, Ahmed Z et al. Oxidative stress is markedly elevated in lecithin:cholesterol acyltransferase-deficient mice and is paradoxically reversed in the apolipoprotein E knockout background in association with a reduction in atherosclerosis. J Biol Chem 2002;277:11715-20.
50. James RW, Deakin SP. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic Biol Med 2004;37:1986-94.
51. deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol 2008;51:2199-211.
52. Triolo M, Annema W, Dullaart RP, Tietge UJ. Assessing the functional properties of high-density lipoproteins: an emerging concept in cardiovascular research. Biomark Med 2013;7:457-72.
53. Albers JJ, Chen CH, Adolphson JL. Lecithin:cholesterol acyltransferase (LCAT) mass; its relationship to LCAT activity and cholesterol esterification rate. J Lipid Res 1981;22:1206-13.
54. Spahr C, Kim JJ, Deng S, Kodama P, Xia Z, Tang J et al. Recombinant human lecithin-cholesterol acyltransferase Fc fusion: analysis of N-and O-linked glycans and identification and elimination of a xylose-based O-linked tetrasaccharide core in the linker region. Protein Sci 2013;22:1739-53.
55. Kumon Y, Nakauchi Y, Kidawara K, Fukushima M, Kobayashi S, Ikeda Y et al. A longitudinal analysis of alteration in lecithin-cholesterol acyltransferase and paraoxonase activities following laparoscopic cholecystectomy relative to other parameters of HDL function and the acute phase response. Scand J Immunol 1998;48:419-24.